General News

Research Discloses Side Effects Of Breast Cancer Drug On Brain Function

Research Discloses Side Effects Of Breast Cancer Drug On Brain Function

Research Discloses Side Effects Of Breast Cancer Drug On Brain FunctionComprehensive research of monkeys in which they were administered the breast cancer drug letrozole discloses its side effects on the brain. Available in The Journal of Neuroscience, the study establishes the widespread marmoset as a key nonhuman primate structure for researching the effects of estrogen-minimizing treatments on the nervous system.

Letrozole is employed in the prevention of breast cancer relapse by interfering with the estrogens production. Even though the side effects such as mood swings and memory problems have been reported in both animals and humans, very less is known regarding how the drug impacts the brain. Nicole Gervais and associates administered Letrozole to male and female monkeys for about 4-weeks period. They noticed many of the similar behavioral variations. It included hot flashes and enlarged anxiety, experienced by women with similar treatment. Letrozole was also found to compromise the working of neurons in the hippocampus and damaged spatial memory.

On a similar note, a new hope for individuals with a severe type of bone marrow cancer came forward as novel research into the remedial drug has revealed advanced outcomes and survival ratios. In the largest research of its type, scientists at Newcastle University, the U.K., headed the national research into treating individuals with recently diagnosed myeloma. The outcomes of this study are available in the journal The Lancet Oncology.

This study highlights progress for those who received existing therapy with lenalidomide, compared to those not receiving it. The research highlighted that long-running treatment with lenalidomide is found to double the shrinking time. It also advances the survival rate in younger individuals by almost 8%. Graham Jackson, Professor, Northern Institute for Cancer Research, Newcastle University, headed the UK-wide study. He stated that the latest study is the big step and, notably, it learns that lenalidomide advances the standard survival rate of younger individuals for this difficult-to-treat bone marrow cancer.